10.1002_adhm.201800296.pdf
[Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 0, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='FULL PAPER\nTheranostics www.advhealthmat.de\nAmplifying Apoptosis Homing Nanoplatform for Tumor\nTheranostics\nHeng Zhao, Ping Zhou, Kai Huang, Guang Deng, Zhiguo Zhou,* Jing Wang,\nMingwei Wang, Yingjian Zhang,* Hong Yang, and Shiping Yang*\nwas achieved by the enhanced perme-\nNanomedicine has significantly impacted cancer theranostics. However, its ability and retention (EPR) effect due\nefficiency is restricted by the limited enhanced permeability and retention to hypervasculature, defective vascular\narchitecture, and impaired lymphatic\neffect of nanomaterials and insufficient density/specificity of receptors of\ndrainage of tumors, whose effectiveness\ntumor cells. Herein, an apoptosis-homing nanoplatform based on zinc(II)\nwas thus hampered by the limited EPR\ndipicolylamine (ZnDPA) conjugated Fe/Fe 3O 4 nanoparticles (MNPs/ZnDPA), effect on different tumor models.[2] Alter-\nwhich demonstrates amplified magnetic resonance signal and photothermal natively, the active targeting strategy by\ntherapy, is developed. In an apoptotic xenograft model constructed by doxo- the receptor-mediated endocytosis into\nrubicin, due to the high affinity between ZnDPA and the upregulated level of overexpressed cancer cells improved the\ntumor-targeting ability to a certain degree.\nphosphatidylserine on the outer surface of apoptotic cancer cells, the accumu-\nNevertheless, the insufficient density and\nlation value of MNPs/ZnDPA is enhanced two-fold and the tumor/muscle\nspecificity of receptors of tumor cells still\nratio of T 2 values is decreased to 50% compared to that in the normal xeno- limits the efficiency of tumor-targeting\ngraft model. In the apoptotic xenograft model, the amplifying photothermal property.[3] Upregulating the number of\ntherapy is confirmed by the changes of the relative tumor volume and terminal existing targets or producing the expres-\nsion of novel targets is a promising\ndeoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling staining.\nstrategy to address the limitations of these\nThis nanoplatform provides a promising strategy to improve the targeting effi-\nconventional tumor-targeting approaches.\nciency of nanoparticles and the enhancement of tumor-targeting theranostics.\nAs a well-accepted target in cancer therapy,\nphosphatidylserine (PS), normally locating\nin the inner cell membrane of normal\n1. Introduction cells, translocates to the surface of apoptotic cells,[4] and its\nexpression can further be elevated as a response to enhanced\nWith the development of nanotechnology, nanomaterials have apoptosis during the cancer therapy. Therefore, the apoptosis-\nsignificantly contributed to cancer theranostics for their attrac- dependent PS level provides a chance to improve the targeting\ntive features of controllable size and tailorable functional prop- efficiency of nanoparticles and results in the enhancement\nerties.[1] The tumor-homing ability of nanomaterials plays a of tumor theranostics.[5] To realize effective tumor imaging\nkey role in achieving their cancer precision theranostics. Gen- and therapy simultaneously, organic nanoparticles[6] and iron\nerally, the passive tumor-targeting property of nanomaterials oxide nanoparticle-based hybrid platforms[7] have been widely\nH. Zhao, P. Zhou, G. Deng, Prof. Z. G. Zhou, J. Wang, Prof. H. Yang, Prof. M. W. Wang, Prof. Y. J. Zhang\nProf. S. P. Yang Department of Nuclear Medicine\nThe Key Laboratory of Resource Chemistry of Ministry of Education Fudan University Shanghai Cancer Center\nShanghai Key Laboratory of Rare Earth Functional Materials, and Shanghai 200032, China\nShanghai Municipal Education Committee Key Laboratory of Molecular E-mail: yjzhang111@aliyun.com\nImaging Probes and Sensors Prof. M. W. Wang, Prof. Y. J. Zhang\nShanghai Normal University Department of Oncology\nShanghai 200234, China Shanghai Medical College\nE-mail: zgzhou@shnu.edu.cn; shipingy@shnu.edu.cn Fudan University\nDr. K. Huang Shanghai 200032, China\nKey Laboratory of Optoelectronic Devices and Systems of Ministry of Prof. M. W. Wang, Prof. Y. J. Zhang\nEducation and Guangdong Province Shanghai Engineering Research\nShenzhen University Center for Molecular Imaging Probes\nShenzhen 518060, China Shanghai 200032, China\nThe ORCID identification number(s) for the author(s) of this article\ncan be found under https://doi.org/10.1002/adhm.201800296.\nDOI: 10.1002/adhm.201800296\nAdv. Healthcare Mater. 2018, 1800296 1800296 (1 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 1, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\nScheme 1. The schematic synthetic illustration of MNPs/ZnDPA, the amplifying MR imaging, and NIR-driven photothermal therapy for apoptotic tumors.\ndeveloped. Recently, photothermal therapy has attracted great PEG-phospholipid and DBCO-phospholipid (w/w, 8:2) by self-\ninterest in the field of cancer therapy due to a minimal attenu- assembly to form DBCO-functionalized MNPs (MNPs/DBCO).\nation of the energy and undesirable thermal damage to healthy Through strain-promoted click reaction,[13] MNPs/DBCO was\ntissue. Many novel nanoparticulate photothermal therapies conjugated with zinc(II) N,N-bis(2-picolyl-2-azidoethyl)amine\nhave already been developed.[8] (ZnDPA-N ) to form ZnDPA-modified MNPs (MNPs/ZnDPA,\n3\nAccording to the above principle, our strategy is to Scheme 1). For the following control experiment, PEGylated\nupregulate the apoptosis degree of tumor by an anticancer drug MNPs (MNPs/PEG) were synthesized with only PEG-phos-\ndoxorubicin (DOX)[9] and thus to increase the level of phosphati- pholipids (Figure S2, Supporting Information). To confirm\ndylserine (PS) in the tumor. The upregulated PS is leveraged the successful conjugation of ZnDPA on the surface of MNPs,\nas the receptor to improve the targeting efficacy of apoptosis we used matrix assisted laser desorption ionization-time of\nhoming nanoparticles. Drug-induced PS have been generally flight-mass spectrometer (MALDI-TOF-MS) to characterize the\nused as biomarkers for apoptosis,[10] however, to the best of our strain-promoted click reaction between DSPE-PEG -DBCO\n2000\nknowledge, this strategy has never been used to amplify the effi- and ZnDPA-N . The results indicated that the molecular weight\n3\nciency of tumor theranostics. Herein, we constructed zinc(II) of the product was increased to ≈3524.6 Da, which was resulted\ndipicolylamine (ZnDPA) conjugated Fe@Fe O NPs (MNPs/ from the formation of DSPE-PEG -ZnDPA (Figure S3, Sup-\n3 4 2000\nZnDPA), in which ZnDPA exhibits the high affinity with PS[11] porting Information). As shown by transmission electron\nand Fe@Fe O NPs presents the high transverse relaxation.[12] microscopy (TEM) images (Figure 1A,B), the average diam-\n3 4\nAs a proof of concept, their amplification of the accumulation eter of MNPs/ZnDPA was 13.0 ± 1.2 nm. The hydrodynamic\nof MNPs/ZnDPA, MR signal, and photothermal therapy for diameter (HD) was determined to be ≈36.5 nm (Figure 1C).\ntumor in vivo were investigated in detail on the apoptotic 4T1 MNPs/ZnDPA displayed the excellent colloidal stability within\nxenograft models with the different levels of PS expression. half a month in both water and saline solution confirmed by\ntheir unchanged HDs, which provided great potential for the\nbiomedical application (Figure 1D).\n2. Results and Discussion\n2.1. Synthesis and Characterizations of MNPs/ZnDPA 2.2. Targeting Property of MNPs/ZnDPA In Vitro\nFe@Fe O nanoparticles (MNPs) were prepared and char- Before the application of MNPs/ZnDPA in vivo, the in vitro\n3 4\nacterized according to our previous report (Figure S1, Sup- cytotoxicity was investigated on 4T1 (tumor cell) and human\nporting Information).[12b] The MNPs were then modified with umbilical vascular endothelial cells (HUVEC) (normal cell)\nAdv. Healthcare Mater. 2018, 1800296 1800296 (2 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 2, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\nFigure 1. A) TEM image and photograph (inset), B) the diameter distribution, and C) hydrodynamic diameter of MNPs/ZnDPA. D) The changes of\nthe hydrodynamic diameters (HDs) as a function of time and photographs (inset) of MNPs/ZnDPA in water and saline solution (0.9% NaCl aqueous\nsolution), respectively.\ncell lines (Figure S5, Supporting Information) via a standard was generated from attached MNPs/FITC/ZnDPA, while\nMTT (methylthiazolyl tetrazolium) assay. The cell viability was red fluorescence signal was originated from DOX. The fluo-\nhigher than ≈90% with the concentration up to 200 µg mL−1 rescence of DOX in all three groups (apoptotic group, target\nafter 24 h incubation, indicating their low cytotoxicity of MNPs/ group, and block group) was set as an internal standard to\nZnDPA. Considering the high transverse relaxation of Fe@ conduct a quantitative analysis of the fluorescence intensity.\nFe O NPs,[12b] to evaluate the apoptosis-targeted property As shown in Figure 2B,C, apoptotic 4T1 cells only showed rela-\n3 4\nof MNPs/ZnDPA, we measured the T values by a 0.5 T MR tive low green fluorescence signal. The fluorescence intensity\n2\nsystem for normal and apoptotic 4T1 cells induced by DOX ratio of green channel to red channel was only ≈0.30. In sharp\n(5 µg mL−1, 4 h), which were both incubated with MNPs/ contrast, after apoptotic 4T1 cells were incubated with MNPs/\nZnDPA (100 µg mL−1) for 2 h, respectively. After the incubation, FITC/ZnDPA, a strong green fluorescence signal was observed.\nthe apoptotic 4T1 cells showed significant higher ΔT /T value Therefore, the fluorescence intensity ratio of green channel to\n2 2\n(≈88%) than that of normal 4T1 cells (≈71%) (Figure 2A). Com- red channel increased to ≈0.94, which was ≈3 times higher than\npared to that of normal 4T1 cells, the amplification of MR signal that of apoptotic 4T1 cells. The enhanced green fluorescence\nin apoptotic 4T1 cells should be attributed to the specific inter- was attributed to the improved accumulation of MNPs/FITC/\naction between PS outside the cell membrane of apoptotic 4T1 ZnDPA in apoptotic cells. Whereas, in the block group, the flu-\ncells and ZnDPA on the surface of MNPs.[11b] However, in the orescence intensity ratio of green channel to red channel was\nblock group, the ΔT /T value of apoptotic 4T1 cells decreased to ≈0.42, indicating ZnDPA inhibited the PS binding with MNPs/\n2 2\n≈75%. The MR imaging results in vitro suggested that MNPs/ FITC/ZnDPA. All the results confirmed MNPs/ZnDPA exhib-\nZnDPA can specifically amplify T -weighted MR signal through ited the excellent targeted property to apoptotic cells.\n2\nZnDPA-mediated cellular binding in apoptotic tumor cells.\nTo verify the apoptosis-targeted property of MNPs/ZnDPA,\nfluorescein isothiocyanate (FITC) was labeled on the surface of 2.3. Targeting Property of MNPs/ZnDPA In Vivo\nMNPs (named as MNPs/FITC/ZnDPA, Figure S4, Supporting\nInformation), and was subsequently imaged by confocal laser Encouraged by the excellent apoptosis-targeted property and\nscanning microscopy (CLSM). As observed by CLSM, after the high transverse relaxation of MNPs/ZnDPA in vitro, we\napoptotic 4T1 cells incubation with MNPs/FITC/ZnDPA investigated their amplification of the accumulation and MR\n(100 µg mL−1), compared to the normal and block group, the imaging in vivo tumor. Two apoptotic tumor models (apoptotic\nmore intense of green fluorescence signal in apoptotic group I and II 4T1 tumor-bearing mice, respectively) were constructed\nAdv. Healthcare Mater. 2018, 1800296 1800296 (3 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 3, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\nand apoptotic II groups with a dose of 10 mg\nkg−1, respectively. The amplifying apoptosis-\nhoming accumulation of MNPs/ZnDPA in\nvivo was first quantificationally investigated\nby inductively coupled plasma mass spec-\ntrometry (ICP-MS). At different time point,\nthe value of %ID g−1 (Injected dose per gram\nof tumor) Fe was analyzed. As shown in\nFigure 3A and Table S1 (Supporting Informa-\ntion), after intravenous injection of MNPs/\nZnDPA for 3 h, the values of %ID g−1 Fe in\nthe tumor were determined to be 2.6 ± 1.0,\n2.2 ± 1.7, and 10.6 ± 6.8% for normal, apop-\ntotic I, and apoptotic II group, respectively.\nHowever, with the intravenous injection\nof MNPs/PEG with no apoptosis-targeting\nproperty for 3 h with the same dose, the\nvalue of %ID g−1 Fe in tumor was similar\nfor all three groups (1.5 ± 5.6, 1.5 ± 2.2, and\n5.2 ± 9.1% for normal, apoptotic I, and apop-\ntotic II group, respectively). The accumula-\ntion amount of MNPs/PEG slight increased\nwith the increase of the apoptosis degree\nprobably resulted from the enhanced tumor\npermeability. For MNPs/ZnDPA, with the\nhigh affinity between PS and ZnDPA, more\nMNPs/ZnDPA were accumulated in tumor\nbecause more PS should be distributed on\nthe cell surface with the increase of the\napoptotic degree.[15] Compared to that of\nthe normal group, the value of %ID g−1 Fe\nin tumor increased to 12.4 ± 1.8% in apop-\ntotic II group from 5.9 ± 3.1%. Through the\nanalysis of Fe in the tumor by ICP-MS on\napoptotic xenograft models with the different\nFigure 2. A) The ΔT/T value and T-weighted MR imaging (up) of normal and apoptotic 4T1 cells apoptotic degree, the amplifying apoptotic-\n2 2 2\nincubated with MNPs/ZnDPA for 2 h at 37 °C on a 0.5 T MR system, respectively. ***P < 0.001 targeted accumulation of MNPs/ZnDPA in\nversus any other group. B) Confocal laser scanning microscopy images of apoptotic 4T1 cells vivo was confirmed.\nincubated with MNPs/FITC/ZnDPA for 2 h at 37 °C (from left to right: bright field of apoptotic\n4T1 cells; green channel collected from 515 to 535 nm; red channel collected from 575 to 595 nm;\noverlay field between green and red channel). Normal group: 4T1 cells; apoptotic group: 4T1 cells\n2.4. Amplifying Apoptosis-Targeted MR\ninduced by DOX (5 µg mL−1) for 4 h; Target group: 4T1 cells induced by DOX (5 µg mL−1) for 4 h,\nImaging In Vivo\nthen incubated with MNPs/ZnDPA (A) and MNPs/FITC/ZnDPA (B) for another 2 h, respectively;\nBlock group: apoptotic 4T1 cells incubated with ZnDPA (1 mg mL−1) for 0.5 h, and then incu-\nbated with MNPs/ZnDPA (A) and MNPs/FITC/ZnDPA (B) for another 2 h, respectively. C) The The amplifying apoptosis-targeted T -\n2\nfluorescence intensity ratio of green channel to red channel. The concentration of MNPs/ZnDPA weighted MR imaging in vivo of MNPs/\nand MNPs/FITC/ZnDPA was 100 µg mL−1, respectively. ***P < 0.001 versus any other group. ZnDPA (10 mg kg−1) was studied on 4T1\napoptotic xenograft models with the dif-\nby intravenously injected with DOX (10 mg kg−1) once for ferent apoptotic degree. As shown in Figure 3B, the MR\n2 d and twice for 3 d, respectively.[9] Confirmed by terminal image of tumor became darker and darker with the increasing\ndeoxynucleotidyl transferase-mediated dUTP-biotin nick end- apoptotic degree. At 10 h postinjection, the T MR tumor-to-\n2\nlabeling (TUNEL) staining, 23.4 ± 1.4% positive apoptotic muscle (T/M) value decreased from 1.51 ± 0.10 to 1.03 ± 0.14\ncells were found for normal tumor group, while 33.7 ± 1.1 and to 0.64 ± 0.02 from normal group to apoptotic I to apoptotic\n39.6 ± 1.7% positive apoptotic cells were found for apoptotic I II group (Figure 3C and Table S2, Supporting Information),\nand II groups, respectively (Figure S6, Supporting Information). suggesting the amplification of MR signal in vivo tumor with\nThe degree of apoptosis on the different tumor models was the increasing levels of PS expression. For the same apoptotic\nfurther confirmed by fluorescent TUNEL staining (Figure S7, tumor group (apoptotic I and II groups, respectively), the image\nSupporting Information). The certain level of apoptosis cells in of tumor became darker at 10 h postinjection than that of 3 h.\nnormal tumor tissue was due to the lack of blood supply.[14] MNPs/ Accordingly, the T/M of T values decreased from 1.46 ± 0.04\n2\nZnDPA were intravenously injected on normal, apoptotic I, after 3 h to 1.03 ± 0.14 after 10 h postinjection for apoptotic\nAdv. Healthcare Mater. 2018, 1800296 1800296 (4 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 4, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\nimaging. Apoptotic 4T1 tumor-bearing mice\nwere divided into five groups. The tempera-\nture of tumors under the laser irradiation\n(808 nm, 0.5 W cm−2, 5 min) was shown\nin Figure S8 (Supporting Information). In\ngroup a (Laser group), the temperature of\ntumor increased only ≈2.2 °C under the\nlaser irradiation. To investigate the apoptotic-\ntargeting property of nanoparticles, groups\nb and c were designed. In group b (MNPs/\nPEG + Laser group), which was a control\ngroup of the apoptosis-targeting PTI group,\nthe EPR effect of MNPs/PEG resulted in the\nenrichment of MNPs/PEG in tumor, and the\ntemperature of tumor increased ≈3.6 °C. As\nthe apoptosis-targeting PTI group (MNPs/\nZnDPA + Laser group), the temperature of\ntumor increased ≈4.8 °C, which was resulted\nfrom the combination of the EPR effect\nand apoptosis-targeting property of MNPs/\nZnDPA. To further investigate the amplifying\napoptosis-targeting property of nanoparti-\ncles, followed by the first PTI, MNPs/PEG\n(group d) and MNPs/ZnDPA (group e) were\ninjected for the second time plus the laser irra-\ndiation, respectively. While the temperature\nof tumor in group d increased ≈6.1 °C under\nthe same laser irradiation, the temperature of\ntumor in group e increased ≈8.6 °C. Due to\nFigure 3. A) Fe analysis in tumor after MNPs/PEG or MNPs/ZnDPA were injected to three the increased apoptotic degree of tumor and\ndifferent tumor models for 3 and 10 h by ICP-MS, respectively. %ID g−1: injected dose per the amplifying apoptosis-targeting property\ngram of tumor. B) MR imaging and C) the tumor-to-muscle (T/M) contrast ratios of T values\n2 of MNPs/ZnDPA, more nanoparticles were\nof three different tumor models before and after the intravenous injection of MNPs/ZnDPA\nenriched in the apoptotic tumor and resulted\nfor 3 and 10 h by a 7 T MR imaging scanner, respectively. Normal group (gray): 4T1 tumor-\nbearing mice without treatment of DOX; Apoptotic I (brown): 4T1 tumor-bearing mice induced in the highest temperature increasing in\nby DOX (10 mg kg−1) once for 2 d; Apoptotic II (blue): 4T1 tumor-bearing mice induced by group e. The fact provided a great possibility\nDOX (10 mg kg−1) twice for 3 d. Preinjection group: mice without injection; MNPs/PEG-3 and for the amplifying tumor PTI in vivo.\nMNPs/PEG-10 groups: mice injected intravenously with MNPs/PEG for 3 and 10 h, respec-\ntively; MNPs/ZnDPA-3 and MNPs/ZnDPA-10 groups: mice injected intravenously with MNPs/\nZnDPA for 3 and 10 h, respectively. The dose of nanoparticles was 10 mg kg−1 of body weight.\n2.6. Amplifying Apoptosis-Targeted Photo-\nthermal Therapy In Vivo\nI group, and from 0.79 ± 0.08 at 3 h to 0.64 ± 0.02 after 10 h\npostinjection for apoptotic II group. When the postinjection Considering the better amplifying apoptosis-targeting property\ntime was elongated, the amplifying MR signal became more on the apoptotic II model, the amplifying apoptosis-targeting\ndistinct. However, for normal tumor group, almost no change photothermal therapy was investigated on the apoptotic II\nof MR image in the tumor was observed, remaining a T/M ratio model. The mice were devided into eight groups randomly. The\nof ≈1.4 of T values from preinjection to 10 h postinjection. All tumor growth data were presented in Figure 4A–C. Tumors\n2\nthe data demonstrated the preferred amplifying apoptosis-tar- of group 1 (apoptosis group), group 2 (laser group), group 3\ngeted effect of MNPs/ZnDPA in tumor with an increasing level (MNPs/PEG group), and group 4 (MNPs/ZnDPA group)\nof PS expression. all exhibited no significant inhibition. The volume of tumor\nincreased to ≈13-folds after 20 d. To investigate the apoptotic-\ntargeting photothermal therapy of nanoparticles, groups 5 (MNPs/\n2.5. Amplifying Apoptosis-Targeted Photothermal Imaging (PTI) PEG + Laser group) and 6 (MNPs/ZnDPA + Laser group) were\nIn Vivo done. While the volume of tumor in group 5 was an increase by\n≈13-folds, the volume of tumor in group 6 was an increase\nBased on the good amplifying apoptosis-homing property of by ≈9-folds, which was resulted from the good apoptosis-tar-\nMNPs/ZnDPA for apoptotic II group and high photothermal geting property of MNPs/ZnDPA. To further investigate the\nconversion property of MNPs/ZnDPA,[12b] we chose the amplifying apoptosis-targeting PTT, after the first PTT, MNPs/\napoptotic II xenograft tumor as a model to evaluate ampli- PEG (group 7) and MNPs/ZnDPA (group 8) were injected for\nfying apoptosis-targeted property in vivo by the photothermal the second PTT, respectively. The tumor growth in group 7\nAdv. Healthcare Mater. 2018, 1800296 1800296 (5 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 5, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\nFigure 4. A) Photos of tumor-bearing mice in different groups on 0, 12th, and 20th d after the treatments, respectively. B) The changes of the relative\ntumor volume of different groups of mice after various treatments. ***P < 0.001 versus any other group. C) Photos of the tumors collected from dif-\nferent groups of mice on the 20th d. D) H&E and E) TUNEL stained histological images of different groups. F) Statistical analysis of the apoptosis rate\nof different groups by TUNEL assay. ***P < 0.001 versus any other group except (7), **P < 0.01 versus (7). Scale bar is 100 µm for all images. The\n808 nm laser irradiation was 0.5 W cm−2 for 5 min. The dose of MNPs/PEG or MNPs/ZnDPA was 10 mg kg−1 of body weight. (1) Apoptosis group:\nmice injected with DOX (10 mg kg−1 of weight) for twice in 3 d (apoptotic mice); (2) Laser group: apoptotic mice injected with saline (200 µL) plus\nthe laser irradiation; (3) MNPs/PEG group: apoptotic mice injected with MNPs/PEG at 3 h i.v. twice; (4) MNPs/ZnDPA group: apoptotic mice injected\nwith MNPs/ZnDPA at 3 h i.v. twice; (5) MNPs/PEG + Laser group: apoptotic mice injected with MNPs/PEG plus the laser irradiation at 3 h i.v. on\nthe 4th d; (6) MNPs/ZnDPA + Laser group: apoptotic mice injected with MNPs/ZnDPA plus the laser irradiation at 3 h i.v. on the 4th d; (7) MNPs/\nZnDPA + Laser + MNPs/PEG + Laser group: apoptotic mice injected with MNPs/ZnDPA plus the laser irradiation at 3 h i.v. on the 4th d for the first\nphotothermal therapy, and then injected with MNPs/PEG plus the laser irradiation at 3 h i.v. in the 6th d; (8) MNPs/ZnDPA + Laser + MNPs/ZnDPA +\nLaser group: apoptotic mice injected with MNPs/ZnDPA plus the laser irradiation at 3 h i.v. in the 4th d for the first photothermal therapy, and then\ninjected with MNPs/ZnDPA plus the laser irradiation at 3 h i.v. in the 6th d.\ncould be greatly inhibited after the second PTT. After 20 d, the tumor after the first PTT and the amplifying apoptosis-targeted\nvolume of tumor was a negligible increase by ≈1.5-folds. How- property of MNPs/ZnDPA. As shown in Figure 4D,E, TUNEL\never, the volume of tumor in group 8 showed a trend of the staining of tumor slices showed that apoptotic tumor cells were\nablation after 20 d. The excellent photothermal therapy effect in extensively stained brown. The apoptosis rates were 49.8 ± 0.7,\ngroup 8 was contributed to the increase degree of apoptosis in 52.7 ± 2.6, and 57.8 ± 1.2% for group 6, 7, and 8, respectively\nAdv. Healthcare Mater. 2018, 1800296 1800296 (6 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 6, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\n(Figure 4F), which were larger than those of other five control Preparation of MNPs/FITC/ZnDPA: DSPE-PEG (6 mg), DSPE-\n2000\ngroups, further indicating the apoptosis-targeting property of PEG 2000-FITC (2 mg), and DSPE-PEG 2000-DBCO (2 mg) were added\nto a glass vial, and then sonicated to dissolve in chloroform (2 mL).\nMNPs/ZnDPA and their significant ampifying homing pho-\nAfter 0.5 mL of oleic acid-coated MNPs in chloroform (10 mg mL−1)\ntothermal therapy effect. The body weight after various treat-\nwas added to the above mixture and shaken overnight at 37 °C, the\nments showed negligible changes (Figure S9, Supporting\nsolvent was evaporated completely, and then water (5 mL) was added.\nInformation), which indicated the low toxicity in vivo during ZnDPA-N (2 mg) was added to the solution, followed by shaking for\n3\nthe photothermal treatment. 0.5 h. The obtained nanoparticles were purified by dialysis (molecular\nweight cutoff, MWCO 14 000) for 48 h. After dialysis, the dispersion was\nfiltered using the 0.22 µm cellulose acetate syringe filter.\nMTT Assay: Murine breast cancer cells (4T1) and HUVEC were\n3. Conclusion\nobtained from Shanghai Cancer Center & Department of Oncology,\nShanghai, China. 4T1 and HUVEC cells were seeded into a 96-well cell\nIn conclusion, we have successfully developed ZnDPA-conju- culture plate at 5 × 104 cells/well in DMEM, with 10% FBS and 1%\ngated Fe@Fe 3O 4 NPs by the strain-promoted click chemistry. penicillin-streptomycin at 37 °C with 5% CO 2 for 24 h, followed by the\nDue to the high affinity between ZnDPA and PS on the outer treatment with different concentrations of MNPs/ZnDPA (0, 5, 10, 20,\ncell surface of apoptotic cancer cells, MNPs/ZnDPA exhibited 50, 100, and 200 µg mL−1 in DMEM, respectively) for 12 and 24 h,\nrespectively. An amount of 20 µL of MTT (5 mg mL−1) solution was\nthe excellent amplifying apoptosis-targeted MR imaging in\nadded to each well and then incubated for 4 h under similar incubation\ntumor with the different apoptotic degree. Due to the ampli-\nconditions. After the supernatant was washed, the purple formazan\nfying apoptosis-targeted property in the tumor, MNPs/ZnDPA crystal was lysed with DMSO (150 µL). The optical absorption value\ncould be rendered as a nanotheranostic agent for enhanced pho- was measured at 490 nm using a Multiskan MK3 enzyme-linked\ntothermal therapy in vivo. Our work provided a revolutionary immunosorbent assay reader with the absorbance at 630 nm as a\napproach to be an effective theranostic agent for the clinical reference.\nApoptotic Cells Model: Healthy 4T1 cells were seeded in six-well cell\ntransformation of Fe@Fe O nanoparticles in the future. The\n3 4 culture plates and used at 80–90% of confluence. Following a method\nstrategy will open up a new avenue in the field of in vivo tumor-\npreviously reported, 4T1 cells were incubated in DMEM medium\ntargeted theranostics. supplemented with DOX (5 µg mL−1, 4 h) for the activation of PS\nexposure in the cells. Following DOX exposure, DMEM media was\nremoved and replaced with fresh media for further experiments.\n4. Experimental Section T 2-Weighted MR Imaging of Apoptotic Cells In Vitro: Before validating\nthe efficacy of MNPs/ZnDPA for enhancing T MR imaging of tumor\n2\nMaterials: Fe(CO) was purchased from Development of Beijing apoptosis, MNPs/ZnDPA were tested on apoptotic cancer cells at\n5\nChemical Technology Co., Ltd. Branch. Oleylamine (70%), 1-octadecene first. 4T1 cells were divided into five groups, namely, healthy 4T1\n(ODE, 90%), and hexadecylamine (HDA, 90%) were purchased from cells without any treating (normal blank group), healthy 4T1 cells\nSigma-Aldrich. 2,2′-Dipicolylamine (DPA, 98%) and zinc nitrate hexahydrate treated with MNPs/ZnDPA (normal group), apoptotic 4T1 cells\n(Zn(NO)·6HO, 99%) were purchased from Energy Chemical, Inc. (apoptotic blank group), apoptotic 4T1 cells treated with MNPs/\n32 2\nDSPE-PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- ZnDPA (apoptotic group), apoptotic 4T1 cells treated with ZnDPA\n2000\n[methoxy(polyethylene glycol)-2000]) and DSPE-PEG -FITC (fluorescein (1 mg mL−1, 0.5 h) first and then incubated with MNPs/ZnDPA (block\n2000\nisothiocyanate-labeled DSPE-PEG ) were purchased from Nanocs, Inc. group). 4T1 cells of normal group, apoptotic group, and block group\n2000\nDSPE-PEG -DBCO (1,2-distearoyl-sn-glycero-3-phosphoethanolamine- were incubated with MNPs/ZnDPA (100 µg mL−1) for 2 h at 37 °C with\n2000\nN-[dibenzocyclooctyl(polyethylene glycol)-2000] (ammonium salt)) 5% CO, respectively. Then the cells were washed with PBS to remove\n2\nwas purchased from Avanti Polar Lipids, Inc. DOX⋅HCl (doxorubicin the remaining nanoparticles, collected, and resuspended in PBS with\nhydrochloride) was purchased from Aladdin, Inc. 0.5% xanthan gum for MR imaging. All MR imaging was performed at\nCharacterization: TEM was performed using a JEOL JEM-2011 a 0.5 T MR imaging system. T-weighted MR images were measured\n2\ntransmission electron microscope. X-ray diffraction (XRD) was using a traditional spin−echo sequence: TR = 6000 ms, TE = 200 ms,\nmeasured on a Rigaku D/MAX 2250 diffractometer with Cu Kα radiation. RG1 = 25 db, DRG1 = 3, SW = 100 kHz. The ΔT/T value in cells\n2 2\nHydrodynamic diameter was carried out on a Malvern Zetasizer Nano (%) = (T value of only cells −T value of cells incubated with NPs)/T\n2 2 2\nZS model ZEN3600. The hysteresis loop was detected on a Quantum value of only cells × 100%.\nDesign SQUID magnetometer. The relative quantitation of polymer was CLSM Imaging for Apoptotic Cells In Vitro: 4T1 cells were divided into\nidentified by an AB Sciex 5800 MALDI-TOF/TOF. The photothermal three groups, namely, apoptotic 4T1 cells (apoptotic group), apoptotic\ntherapy was performed under the irradiation of an 808 nm laser from 4T1 cells treated with MNPs/FITC/ZnDPA (target group), and apoptotic\nShanghai Xilong Optoelectronics Technology Co., Ltd. Fluorescence 4T1 cells treated with ZnDPA (1 mg mL−1, 0.5 h) first and then incubated\nimaging was performed with a Leica TCS SP5 II inverted microscope. The with MNPs/FITC/ZnDPA (block group). 4T1 cells of apoptotic group,\nconcentration of Fe3+ ions was determined by ICP-MS (VISTAMPXICP target group, and block group were incubated with MNPs/ZnDPA\nVARIAN). The molecular weight was determined by MALDI-TOF-MS (AB (100 µg mL−1) for 2 h at 37 °C with 5% CO. Then the cells were washed\n2\nSCIEX5800). with PBS, and replaced with fresh media for CLSM.\nPreparation of MNPs/ZnDPA: Oleic acid-coated MNPs were Apoptotic Tumor Model: Specific pathogen-free ≈4 weeks old BALB/c\nsynthesized according to a previous report.[12c] DSPE-PEG (8 mg) mice were purchased from Shanghai SLAC Laboratory Animal Co., Ltd.\n2000\nand DSPE-PEG -DBCO (2 mg) were added to a glass vial, and then Animal care and handling procedures were approved by the guidelines\n2000\nsonicated to dissolve in chloroform (2 mL). After 0.5 mL of oleic acid- of the Regional Ethics Committee for Animal Experiments. BALB/c mice\ncoated MNPs in chloroform (10 mg mL−1) was added to the above were subcutaneously xenografted with 4T1 tumor in the right thigh.\nmixture and shaken overnight at 37 °C, the solvent was evaporated After 7–10 d, the tumor volume grew to about 100 mm3 for further\ncompletely, and then water (5 mL) was added. ZnDPA-N[16] (2 mg) experiments. Saline (a) or 10 mg kg−1 DOX was initiated through tail\n3\nwas added to the solution, followed by shaking for 0.5 h. The obtained vein administration, once 2 d (b) or every 3 d for a total of two (c)\nnanoparticles were purified by dialysis (molecular weight cutoff, MWCO times. 1 d after the models established, immunohistochemical H&E and\n14 000) for 48 h. After dialysis, the dispersion was filtered using the TUNEL staining of tumor slices of DOX- or saline-injected mice were\n0.22 µm cellulose acetate syringe filter. performed.\nAdv. Healthcare Mater. 2018, 1800296 1800296 (7 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 7, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\nT-Weighted MR Imaging of Tumor Apoptosis In Vivo: Three models Acknowledgements\n2\n(a, b, and c) of 4T1 tumor-bearing mice were intravenously injected\nwith MNPs/ZnDPA (10 mg kg−1 of body weight). In vivo MR imaging H.Z. and P.Z. contributed equally to this work. This work was\nwas performed on a 7 T Siemens Magnetom Trio system and imaged partially supported by National Natural Science Foundation of China\nwith the different time (0, 3, and 10 h, respectively). T-weighted MR (Nos. 21571130 and 21671135), the Ministry of Education of China\n2\nimaging was done by a fast spin−echo sequence: TR/TE = 2050/32 ms, (IRT_16R49), and International Joint Laboratory on Resource Chemistry\nmatrix size = 256 × 256, FOV = 30 × 32 mm, slice thickness = 1.0 mm, of Ministry of Education (IJLRC).\nscan time ≈20 min. The T relaxation time of the tumor area before and\n2\nafter the injection of MNPs/ZnDPA used a T map multislice multiecho\n2\nsequence (TR/TE = 4275/8 ms, matrix size = 256 × 256, 25 echoes, FOV =\nConflict of Interest\n30 × 32 mm, slice thickness = 1.0 mm). To select a region of interest (ROI)\nwithin the phantom area, the software can automatically calculate the\nThe authors declare no conflict of interest.\nmean T value. T/M (%) = T value of tumor/T value of muscle × 100%.\n2 2 2\nPhotothermal Imaging of Tumor Apoptosis In Vivo: 4T1 tumor-bearing\nmice were divided into five groups randomly: (a) Laser group: mice\ninjected with DOX (10 mg kg−1 of weight) for twice in 3 d (apoptotic Keywords\nmice), then injected with saline (200 µL) plus the laser irradiation; (b)\nMNPs/PEG + Laser group: apoptotic mice injected with MNPs/PEG apoptosis, Fe@Fe 3O 4 nanoparticles, magnetic resonance imaging,\nplus the laser irradiation at 3 h i.v. in the 4th d; (c) MNPs/ZnDPA + photothermal therapy, zinc(II) dipicolylamine\nLaser group: apoptotic mice injected with MNPs/ZnDPA plus the laser\nirradiation at 3 h i.v. in the 4th d; (d) MNPs/ZnDPA + Laser + MNPs/ Received: March 22, 2018\nPEG + Laser group: apoptotic mice after the first PTT, then injected with Revised: April 10, 2018\nMNPs/PEG plus the laser irradiation at 3 h i.v. in the 6th d; (e) MNPs/ Published online:\nZnDPA + Laser + MNPs/ZnDPA + Laser group: apoptotic mice after the\nfirst PTT, then injected with MNPs/ZnDPA plus the laser irradiation at\n3 h i.v. in the 6th d. The changes of temperature of tumor under the laser\nirradiation were monitored by the IR thermal camera. The tumor in the [1] a) B. R. Smith, S. S. Gambhir, Chem. Rev. 2017, 117, 901;\nmice was exposed to an 808 nm laser with a power density of 0.5 W cm−2 b) J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, Nat.\nfor 5 min for PTI on FLIR A300 (USA). The dose of nanoparticles (MNPs/ Rev. Cancer 2017, 17, 20; c) S. Kunjachan, J. Ehling, G. Storm,\nPEG and MNPs/ZnDPA, respectively) was 10 mg kg−1 of body weight. F. Kiessling, T. Lammers, Chem. Rev. 2015, 115, 10907; d) L. Cheng,\nPhotothermal Therapy of Tumor Apoptosis In Vivo: 4T1 tumor-bearing C. Wang, L. Feng, K. Yang, Z. Liu, Chem. Rev. 2014, 114, 10869.\nmice were divided into eight groups randomly (n = 5 per group): (1)\n[2] a) H. Maeda, Adv. Drug Delivery Rev. 2015, 91, 3; b) U. Prabhakar,\nApoptosis group: mice injected with DOX (10 mg kg−1 of weight)\nH. Maeda, R. K. Jain, E. M. Sevick-Muraca, W. Zamboni,\nfor twice in 3 d (apoptosis mice); (2) Laser group: apoptosis mice\nO. C. Farokhzad, S. T. Barry, A. Gabizon, P. Grodzinski, D. C. Blakey,\ninjected with saline (200 µL) plus the laser irradiation (0.5 W cm−2)\nCancer Res. 2013, 73, 2412.\nfor 5 min; (3) MNPs/PEG group: apoptosis mice injected with MNPs/\n[3] a) E. A. Sykes, J. Chen, G. Zheng, W. C. Chan, ACS Nano 2014, 8,\nPEG (10 mg kg−1 of weight) at 3 h i.v. twice; (4) MNPs/ZnDPA group:\napoptosis mice injected with MNPs/ZnDPA (10 mg kg−1 of weight) at 3 5696; b) N. Bertrand, J. Wu, X. Xu, N. Kamaly, O. C. Farokhzad, Adv.\nDrug Delivery Rev. 2014, 66, 2; c) F. Danhier, O. Feron, V. Preat, J.\nh i.v. twice; (5) MNPs/PEG + Laser group: apoptosis mice injected with\nMNPs/PEG plus the laser irradiation at 3 h i.v. in the 4th d; (6) MNPs/ Controlled Release 2010, 148, 135.\nZnDPA + Laser group: apoptosis mice injected with MNPs/ZnDPA plus [4] a) S. Nagata, J. Suzuki, K. Segawa, T. Fujii, Cell Death Differ. 2016,\nthe laser irradiation at 3 h i.v. in the 4th d; (7) MNPs/ZnDPA + Laser + 23, 952; b) V. A. Fadok, D. R. Voelker, P. A. Campbell, J. J. Cohen,\nMNPs/PEG + Laser group: apoptosis mice injected with MNPs/ZnDP D. L. Bratton, P. M. Henson, J. Immunol. 1992, 148, 2207.\nplus the laser irradiation at 3 h i.v. in the 4th d for the first photothermal [5] B. A. Smith, B. D. Smith, Bioconjugate Chem. 2012, 23, 1989.\ntherapy, and then injected with MNPs/PEG plus the laser irradiation at [6] a) L. Huang, Z. Gao, G. Han, Part. Part. Syst. Charact. 2017,\n3 h i.v. for 5 min in the 6th d; (8) MNPs/ZnDPA + Laser + MNPs/ 34, 1700223; b) L. Huang, Z. Li, Y. Zhao, J. Yang, Y. Yang,\nZnDPA + Laser group: apoptosis mice injected with MNPs/ZnDPA plus A. I. Pendharkar, Y. Zhang, S. Kelmar, L. Chen, W. Wu, J. Zhao,\nthe laser irradiation at 3 h i.v. in the 4th d for the first photothermal G. Han, Adv. Mater. 2017, 29, 1604789; c) L. Huang, Z. Li, Y. Zhao,\ntherapy, and then injected with MNPs/ZnDPA plus the laser irradiation Y. Zhang, S. Wu, J. Zhao, G. Han, J. Am. Chem. Soc. 2016, 138,\nat 3 h i.v. in the 6th d. The 808 nm laser irradiation was 0.5 W cm−2 for 14586; d) L. Huang, Y. Zhao, H. Zhang, K. Huang, J. Yang, G. Han,\n5 min. The dose of MNPs/PEG or MNPs/ZnDPA was 10 mg kg−1 of Angew. Chem., Int. Ed. 2017, 56, 14400; e) L. Zhao, X. Wu, X. Wang,\nbody weight. The tumor sizes were measured every other day during\nC. Duan, H. Wang, A. Punjabi, Y. Zhao, Y. Zhang, Z. Xu, H. Gao,\nthe therapy process. The tumor volume was calculated using the\nG. Han, ACS Macro Lett. 2017, 6, 700; f) Y. Zhao, J. Peng, J. Li,\nformula: V = LW2/2 (L = length, W = width). After the photothermal\nL. Huang, J. Yang, K. Huang, H. Li, N. Jiang, S. Zheng, X. Zhang,\ntherapy for 20 d, mice were sacrificed. The tumors were removed for\nY. Niu, G. Han, Nano Lett. 2017, 17, 4096.\nH&E and TUNEL staining.\n[7] a) Y. Hu, S. Mignani, J. P. Majoral, M. Shen, X. Shi, Chem. Soc. Rev.\nStatistical Analysis: Quantitative data were expressed as the means ±\n2018, 47, 1874; b) D. Ma, J. Chen, Y. Luo, H. Wang, X. Shi, J. Mater.\nstandard deviations. The statistical analysis was performed using\nChem. B 2017, 5, 7267; c) P. Wang, J. Yang, B. Zhou, Y. Hu, L. Xing,\none-way analysis of variance (ANOVA) with Tukey’s significant difference\npost hoc test using SPSS18.0 software (SPSS Inc., USA). Comparison F. Xu, M. Shen, G. Zhang, X. Shi, ACS Appl. Mater. Interfaces 2016,\nof age was analyzed using an independent-sample t test; Statistical 9, 47.\nsignificance was defined for P < 0.05. [8] a) X. Cheng, R. Sun, L. Yin, Z. Chai, H. Shi, M. Gao, Adv. Mater.\n2017, 29, 1604894; b) J. Liu, X. P. Zheng, L. Yan, L. J. Zhou,\nG. Tian, W. Y. Yin, L. M. Wang, Y. Liu, Z. B. Hu, Z. J. Gu, C. Y. Chen,\nY. L. Zhao, ACS Nano 2015, 9, 696; c) Q. Wu, Y. Lin, F. Wo, Y. Yuan,\nSupporting Information\nQ. Ouyang, J. Song, J. Qu, K. T. Yong, Small 2017, 13, 1701129.\nSupporting Information is available from the Wiley Online Library or [9] a) D. Ye, A. J. Shuhendler, P. Pandit, K. D. Brewer, S. S. Tee, L. Cui,\nfrom the author. G. Tikhomirov, B. Rutt, J. Rao, Chem. Sci. 2014, 5, 3845; b) Y. Yuan,\nAdv. Healthcare Mater. 2018, 1800296 1800296 (8 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n'), Document(metadata={'source': 'papers/papers/10.1002_adhm.201800296.pdf', 'file_path': 'papers/papers/10.1002_adhm.201800296.pdf', 'page': 8, 'total_pages': 9, 'Creator': 'Adobe InDesign CS6 (Macintosh)', 'ModDate': "D:20180510144829-07'00'", 'Trapped': 'False', 'CreationDate': "D:20180509141202+05'30'", 'Producer': 'Adobe PDF Library 10.0.1; modified using iText 4.2.0 by 1T3XT', 'Subject': 'Advanced Healthcare Materials 0.0:1800296', 'WPS-PROCLEVEL': '3', 'WPS-JOURNALDOI': '10.1002/(ISSN)2192-2659', 'Title': 'Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics', 'WPS-ARTICLEDOI': '10.1002/adhm.201800296'}, page_content='www.advancedsciencenews.com www.advhealthmat.de\nZ. Ding, J. Qian, J. Zhang, J. Xu, X. Dong, T. Han, S. Ge, Y. Luo, [11] a) R. G. Hanshaw, B. D. Smith, Bioorg. Med. Chem. 2005, 13,\nY. Wang, K. Zhong, G. Liang, Nano Lett. 2016, 16, 2686. 5035; b) S. W. Bae, M. S. Cho, A. R. Jeong, B. R. Choi, D. E. Kim,\n[10] a) S. Le Gac, I. Vermes, A. van den Berg, Nano Lett. 2006, 6, W. S. Yeo, J. I. Hong, Small 2010, 6, 1499.\n1863; b) G. A. van Tilborg, W. J. Mulder, P. T. Chin, G. Storm, [12] a) J. Wang, H. Zhao, Z. Zhou, P. Zhou, Y. Yan, M. Wang, H. Yang,\nC. P. Reutelingsperger, K. Nicolay, G. J. Strijkers, Bioconjugate Y. Zhang, S. Yang, ACS Appl. Mater. Interfaces 2016, 8, 19872;\nChem. 2006, 17, 865; c) G. A. van Tilborg, W. J. Mulder, N. Deckers, b) Z. Zhou, Y. Sun, J. Shen, J. Wei, C. Yu, B. Kong, W. Liu, H. Yang,\nG. Storm, C. P. Reutelingsperger, G. J. Strijkers, K. Nicolay, Biocon- S. Yang, W. Wang, Biomaterials 2014, 35, 7470; c) L. M. Lacroix,\njugate Chem. 2006, 17, 741; d) B. A. Smith, W. J. Akers, W. M. Leevy, N. F. Huls, D. Ho, X. Sun, K. Cheng, S. Sun, Nano Lett. 2011, 11, 1641.\nA. J. Lampkins, S. Xiao, W. Wolter, M. A. Suckow, S. Achilefu, [13] a) H. Koo, S. Lee, J. H. Na, S. H. Kim, S. K. Hahn, K. Choi,\nB. D. Smith, J. Am. Chem. Soc. 2010, 132, 67; e) B. A. Smith, I. C. Kwon, S. Y. Jeong, K. Kim, Angew. Chem., Int. Ed. 2012, 51,\nS. T. Gammon, S. Xiao, W. Wang, S. Chapman, R. McDermott, 11836; b) Y. Guo, H. Yuan, W. L. Rice, A. T. Kumar, C. J. Goergen,\nM. A. Suckow, J. R. Johnson, D. Piwnica-Worms, G. W. Gokel, K. Jokivarsi, L. Josephson, J. Am. Chem. Soc. 2012, 134, 19338;\nB. D. Smith, W. M. Leevy, Mol. Pharm. 2011, 8, 583; f) B. A. Smith, c) E. M. Sletten, C. R. Bertozzi, Angew. Chem., Int. Ed. 2009, 48, 6974.\nS. Xiao, W. Wolter, J. Wheeler, M. A. Suckow, B. D. Smith, Apop- [14] K. Wang, M. H. Na, A. S. Hoffman, G. Shim, S. E. Han, Y. K. Oh,\ntosis 2011, 16, 722; g) A. J. Surman, G. D. Kenny, D. K. Kumar, I. C. Kwon, I. S. Kim, B. H. Lee, J. Controlled Release 2011, 154, 214.\nJ. D. Bell, D. R. Casey, R. Vilar, Chem. Commun. 2011, 47, 10245; [15] K. Y. Lin, E. J. Kwon, J. H. Lo, S. N. Bhatia, Nano Today 2014, 9, 550.\nh) L. Wyffels, B. D. Gray, C. Barber, S. K. Moore, J. M. Woolfenden, [16] a) L. Jiao, Q. Qiu, B. Liu, T. Zhao, W. Huang, H. Qian, Bioorg. Med.\nK. Y. Pak, Z. Liu, Bioorg. Med. Chem. 2011, 19, 3425; i) B. A. Smith, Chem. 2014, 22, 6857; b) A. Nadler, C. Hain, U. Diederichsen, Eur.\nK. M. Harmatys, S. Xiao, E. L. Cole, A. J. Plaunt, W. Wolter, J. Org. Chem. 2009, 27, 4593; c) L. Götzke, K. Gloe, K. A. Jolliffe,\nM. A. Suckow, B. D. Smith, Mol. Pharm. 2013, 10, 3296. L. F. Lindoy, A. Heine, T. Doert, A. Jäger, K. Gloe, Polyhedron2 011, 30, 708.\nAdv. Healthcare Mater. 2018, 1800296 1800296 (9 of 9) © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n')]
running chunk_indexing
No / None of the above example sentences are present in the document.
-----
No/ None of the above examples sentences were mentioned in the document.
-----
No / The photothermal ablation therapy for tumors using magnetic nanoparticles (MNPs) as the photothermal conversion agent and zinc diphenylphosphine (ZnDPA) as an apoptosis inducer was first proposed.
-----
No/ There is no mention of the development of new machine learning and deep learning algorithms in this document.
-----
Yes / This nanoplatform provides a promising strategy to improve the targeting efficiency of nanoparticles and the enhancement of tumor-targeting theranostics.
-----
No/ The authors declare no conflict of interest.
-----
No/ None
-----
No/ None
-----
No/ None
-----
No / There is no mention of developing lead small-molecule drug candidates in the provided text snippet. The text appears to be discussing the synthesis and characterization of nanoparticles, specifically MNPs/ZnDPA, for use in MRI imaging and their interaction with apoptotic cells.
-----
No/ None
-----
{'10.1002_adhm.201800296.pdf': {'new materials': {'Yes/No': 'No', 'sentence': ' None of the above example sentences are present in the document.'}, 'screening algorithms': {'Yes/No': 'No', 'sentence': ' None of the above examples sentences were mentioned in the document.'}, 'experimental methodology': {'Yes/No': 'No', 'sentence': ' The photothermal ablation therapy for tumors using magnetic nanoparticles (MNPs) as the photothermal conversion agent and zinc diphenylphosphine (ZnDPA) as an apoptosis inducer was first proposed.'}, 'ML algorithms': {'Yes/No': 'No', 'sentence': ' There is no mention of the development of new machine learning and deep learning algorithms in this document.'}, 'models': {'Yes/No': 'Yes', 'sentence': ' This nanoplatform provides a promising strategy to improve the targeting efficiency of nanoparticles and the enhancement of tumor-targeting theranostics.'}, 'funding': {'Yes/No': 'No', 'sentence': ' The authors declare no conflict of interest.'}, 'material datasets': {'Yes/No': 'No', 'sentence': ' None'}, 'drug formulations explored': {'Yes/No': 'No', 'sentence': ' None'}, 'novel drug formulations': {'Yes/No': 'No', 'sentence': ' None'}, 'lead small-molecule drug candidates': {'Yes/No': 'No', 'sentence': ' There is no mention of developing lead small-molecule drug candidates in the provided text snippet. The text appears to be discussing the synthesis and characterization of nanoparticles, specifically MNPs'}, 'clinical trials': {'Yes/No': 'No', 'sentence': ' None'}}}
